- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
VIVUS Inc. (NASDAQ:VVUS): Jefferies views the FDA’s decision on VIVUS’s weight loss drug, Qnexa, as a 50-50 outcome, but believes that the current price of shares reflects strong optimism for approval. The firm keeps an Underperform rating on the stock with a $9 price target.
Don’t Miss: Is This Facebook-CRUSHED Rival Back in the Game?
Darden Restaurants, Inc. (NYSE:DRI): Jefferies believes that Darden Restaurants, Inc., are a high-quality growth concept in Yard House, but says that shares will likely become lower in the near-term earnings dilution. However, he feels that this acquisition makes Darden more attractive looking over the long-term. There is a Buy rating on the stock.
Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP): Over the longer term, and in spite of what RBC Capital sees as a lackluster performance by Endo’s tamper resistant formulation of Opana, the firm believes that their product will continue to show significant growth. They recommend buying the stock in the near-term.
VMware, Inc. (NYSE:VMW): Heading into the second quarter report with reduced expectations, Morgan Stanley views VMware’s risk/reward as attractive. The firm believes that an inline report, or better will drive shares, which are Overweight rated, back to the $90′s.
Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR): Citing increased competition, Stifel Nicolaus slashed Green Mountain’s FY13 earnings per share estimates from $2.27 to $1.80. The firm expects to lose shares and have reduced their fair value stock to $14, while still maintaining a Sell rating.
Don’t Miss: Is Google Leaving Apple in its DUST?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.